Sorrento Stock Has Multiple Catalysts in Play; Analyst Says ‘Buy’
Some companies favor a "do one job and do it well" approach.
However, that is not the Sorrento Therapeutics (SRNE) way. While
being laser-focused on just one objective can have its advantages,
having a wider-based remit can be just as effective, if done well.
That is certainly the opinion of Alliance Global analyst James
Molloy when evaluating Sorrento’s prospects. “SRNE combines one of
the most active and promising pipelines in the COVID space with a
potentially transformative non-opioid pain pipeline, and adds in a
deep oncology pipeline,” the analyst said.